Guerbet

Guerbet is a global leader in medical imaging, specializing in the research, development, manufacturing, and marketing of contrast agents for diagnostic imaging. Founded in 1926, the company has a rich history that began with the discovery of the first iodinated organic contrast medium, Lipiodol. Guerbet's product portfolio includes contrast agents for X-ray, computed tomography (CT), and magnetic resonance imaging (MRI), with notable products like Elucirem, an MRI contrast agent approved by the U.S. FDA in 2022. The company is committed to digital innovation, collaborating with IBM Watson Health to develop AI solutions that enhance cancer diagnosis and care. With over 2,700 employees and manufacturing sites across several countries, Guerbet operates globally, providing high-quality contrast agents to hospitals, diagnostic imaging centers, and healthcare professionals. Their products support a variety of clinical applications, ensuring accurate diagnosis and improved patient care in the healthcare market.